v3.25.2
Segment Reporting (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]            
Number of operating segments | segment         1  
Number of Reportable Segments | segment         1  
Segment Reporting Information [Line Items]            
Total revenue $ 1,373   $ 1,141   $ 2,854 $ 2,155
Total research and development 8,402   8,902   17,932 15,728
General and administrative 6,766   7,688   13,218 14,092
Total operating expenses 15,168   16,590   31,150 29,820
Loss from operations (13,795)   (15,449)   (28,296) (27,665)
Interest (expense) income, net (1,058)   173   (1,972) 475
Other income (expense), net 114   (4)   179 (14)
Net loss (14,739) $ (15,350) (15,280) $ (11,924) (30,089) (27,204)
Collaborative Arrangements            
Segment Reporting Information [Line Items]            
Total revenue 1,373   1,141   2,854 2,155
Total research and development         1,100 400
Reportable Segment            
Segment Reporting Information [Line Items]            
Research and development personnel costs 4,091   3,164   8,106 5,844
Facilities and other support costs 834   879   1,815 1,377
Other 72   499   1,149 926
Total research and development 8,402   8,902   17,932 15,728
General and administrative 6,766   7,688   13,218 14,092
Total operating expenses 15,168   16,590   31,150 29,820
Loss from operations (13,795)   (15,449)   (28,296) (27,665)
Interest (expense) income, net (1,058)   173   (1,972) 475
Other income (expense), net 114   (4)   179 (14)
Net loss (14,739)   (15,280)   (30,089) (27,204)
Reportable Segment | OCU400            
Segment Reporting Information [Line Items]            
Research and development expense (excluding acquired in process cost) 1,998   2,180   3,843 3,699
Reportable Segment | OCU410 and OCU410ST            
Segment Reporting Information [Line Items]            
Research and development expense (excluding acquired in process cost) 1,117   1,197   2,295 1,681
Reportable Segment | NeoCart            
Segment Reporting Information [Line Items]            
Research and development expense (excluding acquired in process cost) 8   28   5 355
Reportable Segment | COVAXIN            
Segment Reporting Information [Line Items]            
Research and development expense (excluding acquired in process cost) 0   56   0 73
Reportable Segment | Inhaled mucosal vaccine platform            
Segment Reporting Information [Line Items]            
Research and development expense (excluding acquired in process cost) 131   807   319 1,496
Reportable Segment | OCU200            
Segment Reporting Information [Line Items]            
Research and development expense (excluding acquired in process cost) 151   92   400 277
Reportable Segment | Collaborative Arrangements            
Segment Reporting Information [Line Items]            
Total revenue $ 1,373   $ 1,141   $ 2,854 $ 2,155